During the last two decades many genes have been shown to cause autosomal dominant forms of earlyonset dementing illnesses. These rare disorders have provided enormous insight into the pathogenesis ofmore common variants of the same diseases. Several of the most promising new therapeutics are based onthe Afi hypothesis, a hypothesis largely supported by the causative mechanisms of disease mutations inautosomal dominant families. As these putative therapeutics are tested in clinical trials there is a growingneed to use the FAD kindreds both to understand the natural history of the earliest clinical and preclinicalphases of the disease and to test the efficacy of the therapeutics in a setting, where if the Afi hypothesis iscorrect, they should have a dramatic effect on prognosis. The first step in this overarching goal is to bringtogether a network of centers to characterize a large series of FAD kindreds with known disease-causingmutations. The goal of the Genetics Core of the DIAN initiative is to provide genetic information and usefulbiological materials to the research community for the study of AD. We will collect blood samples for DMAextraction from all study participants (n=300). Since these individuals are part of FAD kindreds with knowncausative mutations we will screen each sample for the known mutation in that family and genotype allfamilies for known disease modifying alleles such as APOE e4. Blood from each individual will be sent toNCRAD for transformation to develop lymphoblastoid cell lines that will provide the largest resource of celllines from FAD kindreds with known disease-causing mutations anywhere in the world.
Showing the most recent 10 out of 108 publications
